Hancock Whitney Corp Makes New $296,000 Investment in Astrana Health, Inc. (NASDAQ:ASTH)

Hancock Whitney Corp bought a new position in Astrana Health, Inc. (NASDAQ:ASTH) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 5,104 shares of the company’s stock, valued at approximately $296,000.

Several other hedge funds have also recently bought and sold shares of ASTH. SteelPeak Wealth LLC acquired a new stake in shares of Astrana Health during the third quarter worth approximately $39,398,000. Loomis Sayles & Co. L P acquired a new stake in shares of Astrana Health during the 3rd quarter valued at $30,251,000. NorthCrest Asset Manangement LLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at $26,704,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Astrana Health in the third quarter worth $25,945,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Astrana Health during the third quarter worth $13,383,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Stock Performance

Shares of ASTH opened at $42.86 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health, Inc. has a one year low of $32.32 and a one year high of $63.20. The company’s fifty day moving average price is $53.65 and its 200 day moving average price is $47.98. The company has a market capitalization of $2.41 billion, a PE ratio of 32.97, a price-to-earnings-growth ratio of 1.97 and a beta of 1.24.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter in the previous year, the firm earned $0.47 EPS. As a group, analysts expect that Astrana Health, Inc. will post 1.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ASTH shares. KeyCorp assumed coverage on Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating on the stock. Truist Financial increased their price objective on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, August 9th. BTIG Research lifted their target price on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Stifel Nicolaus increased their price target on shares of Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, Robert W. Baird lifted their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $65.17.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.